Mainz Biomed N.V.
MYNZ
$4.37
-$0.365-7.72%
Weiss Ratings | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Weak | |||
Risk Index | Very Weak | |||
Risk Grade | E+ | |||
Reward Grade | D- | |||
Rating Factors | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Fair | |||
Total Return Index | Very Weak | |||
Volatility Index | Very Weak | |||
Beta / Standard Deviation | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.69 | |||
Price History | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -19.17% | |||
30-Day Total Return | -18.26% | |||
60-Day Total Return | -18.56% | |||
90-Day Total Return | -55.46% | |||
Year to Date Total Return | 1.51% | |||
1-Year Total Return | -89.30% | |||
2-Year Total Return | -98.30% | |||
3-Year Total Return | -99.19% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -89.54% | |||
52-Week Low % Change | 29.59% | |||
Price | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $45.20 | |||
52-Week Low Price | $3.65 | |||
52-Week Low Price (Date) | Dec 18, 2024 | |||
52-Week High Price (Date) | Apr 02, 2024 | |||
Valuation | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 15.94M | |||
Enterprise Value | 23.23M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -32.99 | |||
Earnings Per Share Growth | 52.74% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 4.87 | |||
Price/Book (Q) | 0.77 | |||
Enterprise Value/Revenue (TTM) | 50.09 | |||
Price | $4.37 | |||
Enterprise Value/EBITDA (TTM) | -1.64 | |||
Enterprise Value/EBIT | -1.60 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 477.20K | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 49 6131 554 2860 | |||
Address | -- | |||
Website | mainzbiomed.com | |||
Country | Germany | |||
Year Founded | 2008 | |||
Profitability | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -- | |||
Return on Equity | -- | |||
Income Statement | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | $0.97 | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -- | |||
EBIT (TTM) | -- | |||
Net Income (TTM) | -- | |||
Net Income Avl. to Common (TTM) | -- | |||
Total Revenue Growth (Q YOY) | 11.12% | |||
Earnings Growth (Q YOY) | 36.70% | |||
EPS Diluted (TTM) | -- | |||
EPS Diluted Growth (Q YOY) | 49.70% | |||
Balance Sheet | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 7.07M | |||
Cash Per Share (Q) | $14.82 | |||
Total Current Assets (Q) | 8.98M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 3.25M | |||
Current Ratio (Q) | 0.972 | |||
Book Value Per Share (Q) | $6.14 | |||
Total Assets (Q) | 15.41M | |||
Total Current Liabilities (Q) | 9.24M | |||
Total Debt (Q) | 7.42M | |||
Total Liabilities (Q) | 12.16M | |||
Total Common Equity (Q) | 3.25M | |||
Cash Flow | MYNZ - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -- | |||
Cash from Financing (TTM) | -- | |||
Net Change in Cash (TTM) | -- | |||
Levered Free Cash Flow (TTM) | -- | |||
Cash from Operations (TTM) | -- | |||